CD247抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Jurkat cell lysate, Primary antibody: P09453(CD247 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P09453(CD247 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09453(CD247 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

CD247. also known as CD3ζ (zeta chain), is a critical component of the T-cell receptor (TCR) complex, which plays a central role in adaptive immunity. It is encoded by the *CD247* gene and forms homodimers that associate with CD3γ, CD3δ, and CD3ε subunits to constitute the TCR-CD3 complex on T cells. This transmembrane protein contains immunoreceptor tyrosine-based activation motifs (ITAMs) in its cytoplasmic domain, enabling signal transduction upon antigen recognition. Upon TCR engagement, CD3ζ undergoes phosphorylation, initiating downstream signaling cascades essential for T-cell activation, proliferation, and cytokine production.

Antibodies targeting CD247 are widely used in research and clinical applications. In diagnostics, anti-CD247 antibodies help identify T cells via flow cytometry or immunohistochemistry. Therapeutically, CD3ζ-directed antibodies have been explored in immunomodulation, particularly in bispecific T-cell engagers (BiTEs) or chimeric antigen receptor (CAR) T-cell therapies, where they enhance cytotoxic T-cell responses against tumors. Additionally, monoclonal antibodies like teplizumab (anti-CD3) have shown promise in autoimmune diseases (e.g., type 1 diabetes) by modulating T-cell activity.

CD247 antibodies also aid in studying T-cell signaling defects, immunodeficiency disorders, and TCR-mediated pathologies. Their specificity makes them valuable tools for dissecting mechanisms of immune activation, tolerance, and therapeutic resistance. However, challenges remain in minimizing off-target effects and cytokine release syndromes in clinical applications. Ongoing research focuses on optimizing antibody design to improve efficacy and safety in cancer immunotherapy and autoimmune treatments.